We pledge to design groundbreaking medicines

Our team members have built and exited start-ups, advanced multiple drugs into the clinic, are inventors on FDA approved drugs and cracked multiple “undruggable” targets

Our Team

Ali H. Munawar, Ph.D.

Chief Executive Officer & Founder

Stephen pledge-About us Pledge Therapeutics

Stephen D. Weeks, Ph.D.

Director of Structural Biology

Mark R. Spyvee, D. Phil.

Vice President, Head of Chemistry R&D

Hector R. Lucero, Ph.D.

Director of Biochemistry and Cell Biology

Asanga Bandara, Ph.D.

Computational Chemist

Jeffrey McKinney, Ph.D.

Senior Scientist

Steff de Graef, Ph.D.


Andrej Jedinak, Ph.D.

Associate Director, Immuno-Oncology

Maria Martin-Goula

Maria Martin-Goula

Operations and Human Resources Manager

Our Core Values

reflect a shared passion for the discovery and development of innovative medicines.



We are a cohesive, agile and multidisciplinary team of scientists driven by a single purpose and mission - to improve the lives of patients. We do this by developing medicines with unique and differentiated mechanisms of actions for life-threatening diseases for which there are no adequate treatments.

Dedication to science & discovery


We like to push the boundaries of science and discovery; our research starts where the comfort zone ends. We value candidates that are self-motivated, problem-solvers with a diversity of perspectives, skills, ideas, backgrounds and expertise. We reward passion, scientific rigor, teamwork, respect, efficiency, introspection and transparency.



We offer a competitive salary, health, dental and vision plans, 401k plan, paid time off and sick time, vacations, company stock options, flexible work environment, free parking, fitness facilities, and career growth opportunities.

Join Our Team

If you want to be part of our pledge, we would like to hear from you!
Drop us a line: info@pledge-tx.com

Ali H. Munawar, Ph.D.

Ali is an experienced entrepreneur with a track record of leading discovery projects from ideation to proof-of-concept and executing M&A transactions. He has built biotech startups from the ground up, collectively raising over $50M in seed and venture capital investment for companies that he founded.

Ali was the founding CEO of Novira Therapeutics and led the evolution and growth of Novira and directing its novel approach to targeting virus capsid assembly as an antiviral strategy. His pioneering graduate work in non-enzymatic antiviral inhibitors that disrupt protein-protein interactions led to a Gates Foundation award that propelled Novira. Novira was acquired in 2015 by Johnson & Johnson.

Previously, he led the commercialization strategy, business development, and alliance management functions at the Joslin Diabetes Center, securing over $22M in business deals with multiple Big Pharma companies.

As the CEO, Ali is also a hands-on scientist specializing in difficult to “drug”, frontier targets often referred to as the “high hanging fruits in drug discovery”. He is actively involved in innovative hit and lead generations strategies that have led to the development of drug starting points for over half a dozen drug targets. Ali holds a Master’s in Bioengineering from Harvard University and received a Ph.D. in X-ray crystallography and structure-based drug design from KU Leuven in Belgium.

Ali has a background in strategic consulting, is an active member of various venture and scientific communities. He is involved with early-stage investment, venture creation, and due diligence. He is passionate about paying it forward by mentoring new entrepreneurs. In his spare time, Ali is passionate about animals, nature, and the outdoors.

Stephen D. Weeks, Ph.D.

Stephen brings more than twenty years of experience in the fields of biochemistry and structural biology. Stephen is also the group leader of our Leuven research facilities and coordinates an advanced biophysics-based research program to accelerate our discovery pipeline.

Before joining Pledge, Stephen led a team of researchers at the University of KU Leuven using rational drug design to develop new antibiotics. Previously, Stephen was involved with several innovative programs at Life Sensors Inc in the USA. His original work around the SUMO fusion expression system and the generation of other life sciences tools has impacted protein production across basic research, drug discovery and diagnostic laboratories worldwide.

Stephen carried out his undergraduate studies in biochemistry at the University of Lancaster and US in the US, and he undertook his Ph.D. at the European Molecular Biology Laboratories in Heidelberg, Germany. He has over 40 peer-reviewed publications and is responsible for nearly 90 structures in the public Protein Data Bank. Reflecting on his cross-border international experience Stephen is passionate about bringing together the brightest minds to drive success.

Mark R. Spyvee, D. Phil.

Mark is a seasoned Medicinal Chemist who has contributed to the development of 17 innovative small molecules, including 8 compounds that reached clinical development and 1 FDA approved product. At Pledge, Mark strategizes lead finding, lead optimization, and medicinal chemistry to create novel clinical candidates and develops pre-clinical candidate compounds to enable INDA filing.

Mark spent 14 years at Eisai Pharmaceuticals, a multinational pharma company, in various roles; most recently, he was Director of Medicinal Chemistry and co-Head of the Immunology group at Eisai US, UK, and Japanese sites. He oversaw multidisciplinary teams working on lead finding, optimization, and pre-clinical development efforts, yielding drug candidates for rheumatoid arthritis, lupus, psoriasis, sepsis, infectious diseases, oncology, and immune-oncology. In addition to R&D roles, Mark has previously held the position of VP of Business Development at Sai Life Sciences, where he managed a portfolio of over 30 biotech and pharma clients. Mark has also actively been a Medicinal Chemistry consultant to over 16 companies.

Prior to Eisai, Mark was involved with the development of multiple insecticidal and antifungal programs at ICI Agrochemicals, including the billion-dollar product, azoxystrobin.

Mark has co-authored 65 publications and is a co-inventor on 37 patents. He received his doctorate at the University of Oxford with Prof. Sir Jack Baldwin, FRS, and completed his post-doc fellowship at UT Austin with Prof. Phil Magnus, FRS. In his spare time, Mark loves to enjoy the great outdoors, especially oceans, ski slopes and the racetrack.

Hector R. Lucero, Ph.D.

Dr. Lucero brings more than 30 years of experience in industry and academia. At Pledge Therapeutics, he is in charge of early validation of hits and established mammalian cell culture, a BLS-2 laboratory to process and analyze tens of cell lines and primary cells, and lead scientist’s work at our facilities in Canton, US.

Before joining Pledge Therapeutics,Hector held a faculty position at Boston University, where he led industry collaborations with Bristol-Myers, Squibb, and Hoffman La-Roche. His work focused on the analysis and identification of the Yhns 4 ATPase of the proteasome 20 S subunit. Previous to that, he was at Agrivida, an Agritech company, where he led the Plant Analysis team, coordinating research & development, and implementing biochemical and cell biology strategies. Hector also made key contributions to Agrivida patents and proprietary technology.

Hector obtained his Ph.D. at the University of Buenos Aires and completed his post-doctoral training with Dr. Efraim Racker, founder of the Biochemistry Department at Cornell University, and member of the American Academy of Arts and Sciences. In Dr. Racker’s laboratory, Hector started the molecular cloning of a yeast protein whose mammalian equivalent is an essential subunit of the proteasome complex involved in cellular homeostasis.

Hector is passionate about mentoring young scientists with diverse scientific and technological backgrounds, and he earned his credentials as an extraordinary advisor in his participation at the Molecular Biology, Cell Biology at Brown University.

Asanga Bandara, Ph.D.

Asanga manages our computational chemistry and computational drug discovery effort. His work is in the application of computational chemistry, cheminformatics, and bioinformatics in the pursuit of novel small molecule drugs. Asanga also assists with the ongoing systems biology and biophysics efforts at Pledge through in-silico modeling, molecular dynamics (MD) and Monte Carlo (MC) simulation, establishing data analysis platforms for high-throughput assays, and utilization of machine learning and deep-learning based methods. His work leverages high-performance computing systems. At Pledge, Asanga has put together a state-of-the-art workflow that enables us to sample a vast universe of drug compounds in experimentally validated models generated by our interdisciplinary team.

Asanga earned his Ph.D. at Boston University, working on biophysical and statistical mechanical aspects of protein-protein and lipid-protein interactions pertinent to neurodegenerative diseases. He is passionate about the use of experimentally directed computational research and its future in the life sciences.

Jeffrey McKinney
Jeffrey coordinates Protein Purification and Crystallization efforts in the Canton location. As a Senior Scientist, Jeffrey is responsible for purifying our targets of interest and conducting various orthogonal assays, like spectroscopic and calorimetric measurements as well as enzyme kinetics determinations to elucidate binding modes of our compounds of interest. Jeffrey ‘s passion for drug discovery was ignited while working as research assistant in the Pharmacology Dept. at the Mayo Clinic in Rochester, MN. He trained in protein crystallization and crystallography at the Hauptman Woodward Institute and University of Buffalo in New York where he led the protein expression, purification and crystallization pipeline for novel THz spectroscopy measurements of vibrational modes in protein crystals with the aim of identifying allosteric mechanistic modes.Jeffrey earn his PhD (2005) in Molecular Biology and Biochemistry at the University of Bergen in Norway where he characterized ligand binding modes to the tryptophan hydroxylase enzymes and the role of disease associated mutants in serotonin biosynthesis. Jeffrey is passionate about drug discovery and generating medicines of the future.
Steff de Graef

Steff coordinates our Protein Purification efforts in our Leuven location. As a junior Scientist, Steff is responsible for purifying our targets of interest and conducting various orthogonal assays, like protein crystallization that provides insights into the binding mode of our compounds of interest, or biophysical experiments to obtain binding affinities and cross-validate target engagement. With this data, Steff provides insights to help the rational design of new improved compounds.

Steff obtained his MSc in Drug Development and qualified as a Pharmacist (KU Leuven 2015). He later pursued his Ph.D. in Pharmaceutical Sciences (KU Leuven 2020). He joined Pledge Therapeutics with the passion to provide frontline insights on how a small molecule can impact the quality of life of patients that suffer unmet clinical needs.

Andrej Jedinak, Phd
Andrej leads our Immune-Oncology programs at Pledge Therapeutics. With over seventeen years of experience in academia and industry, his expertise expands from preclinical and translational oncology, immune-oncology and drug development research. Over his career, he gained expertise in small and large molecules, nucleic acids (RNAi), antibodies and antibody-fusion molecules. Before joining Pledge Therapeutics, Andrej completed his postdoctoral training at Methodist Research Institute, Indiana University and at the Vascular Biology Program at Boston Children’s Hospital and Harvard Medical School. Andrej has industry experience from working at Phio Pharmaceuticals Inc, where he helped to establish adaptive and innate immunity programs to test self-delivering RNAi (INTASYL) compounds as immune-oncology therapeutics. Most recently, Andrej worked at Agenus Inc, where he oversaw the program developing antibody-fusion therapeutic targeting immune-suppressive tumor microenvironment. Andrej holds a PhD in Biotechnology from the Slovak University of Technology in Bratislava, Slovakia. Andrej enjoys outdoor activities in his free time, including hiking, biking, skiing, and ice skating.
Maria Martin-Goula

Maria oversees and harmonizes the day-to-day operational planning,
collaborates with the scientific teams to streamline processes and systems
and manages Human Resources functions and the business administration in Leuven and Canton.

Previously Maria worked at Tax Consultancy, in the Human Resources and
Contractual area for small businesses in Barcelona. Later she spent over four years at the United Nations Associations in Spain (UNA-Spain) and the World federations of UNA (WFUNA) in New York as Model-UN Coordinator, where she worked with WFUNA associations worldwide, collaborating on the design, development and implementation of international conferences.
Maria also has experience as Diversity, Equity and Inclusion consultant,
delivering focused trainings and consultancy to executives and leaders across sectors at local and international level.

Maria earned a BA in Political Science and a Degree in Labor Relations from
Universitat Autonoma de Barcelona. She earned a M.A. focused on Diversity
and Inclusion at Yale University. In her free time, Maria enjoys outdoor